Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2010 August;51(4) > The Journal of Cardiovascular Surgery 2010 August;51(4):591-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  TREATMENT OF IN-STENT RESTENOSIS IN PERIPHERAL ARTERIES 

The Journal of Cardiovascular Surgery 2010 August;51(4):591-8

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Prevention and treatment of in-stent restenosis

Bosiers M. 1, Deloose K. 1, Keirs K. 2, Verbist J. 2, Peeters P. 2

1 Department of Vascular Surgery, AZ St-Blasius, Dendermonde, Belgium; 2 Department of Cardiovascular & Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium


PDF


In-stent restenosis has always been an important issue, since the launch of the first stents on the market. The occurrence of in-stent restenosis (ISR) is due to two main reasons. First, the presence of stent fractures significantly influences restenosis rates. Second, the continuous interaction between the permanently implanted artificial material and the vessel tissue, leads to physical irritation, long-term endothelial dysfunction, or chronic inflammatory reactions. In the Literature only very limited data on ISR treatment in the peripheral arteries are available. There are no peer-reviewed publications or studies with in-depth follow-up on this specific indication. The underlying reason for this probably being that currently available treatments do not yield satisfactory results. However, the continuing search for better solutions and the technological evolution lead to the introduction of the Viabahn with PROPATEN coating, DES and DCB, which may result in the first promising treatment options for ISR.

top of page